Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives
about
Inhibition of human immunodeficiency virus type 1 replication in acutely and chronically infected cells by EM2487, a novel substance produced by a Streptomyces speciesInhibition of acute-, latent-, and chronic-phase human immunodeficiency virus type 1 (HIV-1) replication by a bistriazoloacridone analog that selectively inhibits HIV-1 transcriptionEthyl 4-(3-hydroxy-phen-yl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexa-hydro-quinoline-3-carboxyl-ate.Ethyl 2-methyl-5-oxo-4-(3,4,5-trimeth-oxy-phen-yl)-1,4,5,6,7,8-hexa-hydro-quinoline-3-carboxyl-ate.Impact of Tat Genetic Variation on HIV-1 DiseaseInhibition of Tat-mediated HIV-1 replication and neurotoxicity by novel GSK3-beta inhibitors.Cytotoxicological analysis of a gp120 binding aptamer with cross-clade human immunodeficiency virus type 1 entry inhibition properties: comparison to conventional antiretroviralsNovel neuroprotective GSK-3β inhibitor restricts Tat-mediated HIV-1 replication.Strategies to Block HIV Transcription: Focus on Small Molecule Tat Inhibitors.Inhibition of human immunodeficiency virus type 1 replication by combination of transcription inhibitor K-12 and other antiretroviral agents in acutely and chronically infected cellsNew anti-human immunodeficiency virus type 1 6-aminoquinolones: mechanism of action.Novel in vivo model for the study of human immunodeficiency virus type 1 transcription inhibitors: evaluation of new 6-desfluoroquinolone derivatives.Inhibition of human immunodeficiency virus type 1 tat-trans-activation-responsive region interaction by an antiviral quinolone derivative.A 6-aminoquinolone compound, WC5, with potent and selective anti-human cytomegalovirus activity
P2860
Q28343602-372DE03B-3C4B-4C20-B76E-936F8574B01DQ28379402-B48AE763-D364-45F4-A050-126FC876B1F2Q34270485-7C2CF890-0DAF-40F6-AE0E-10BBBBA305DDQ34431352-87956C1B-9A94-448C-AB25-BCF7B1A7B3A7Q36148507-D6FEFCE3-F13A-4433-8F8C-CA9213DA4064Q36915824-A38FEBB5-2033-45AD-95AB-A651AABF1213Q37247615-235A6874-D1CB-45FD-8930-A60F87A38DBCQ37547409-188720E9-FA43-4C8C-B50B-1A97DD8A01F7Q38212101-E4A3A651-1BA0-43AE-BE7D-6260B8A1860EQ39470193-2FA5C565-225B-40F1-A9B7-169B68DD94ADQ39731930-20505702-D716-4ED5-B22B-7862EFFF4B5DQ40180319-FDC1CC41-8578-41A1-A054-E7349750FDD0Q40815938-439F07B6-5DAB-48A0-B7E2-EED5F841FA51Q42147352-AD0637E1-86B2-428B-8610-B101B29F0C33
P2860
Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives
description
1997 nî lūn-bûn
@nan
1997 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Potent and selective inhibitio ...... azinyloxoquinoline derivatives
@ast
Potent and selective inhibitio ...... azinyloxoquinoline derivatives
@en
Potent and selective inhibitio ...... azinyloxoquinoline derivatives
@nl
type
label
Potent and selective inhibitio ...... azinyloxoquinoline derivatives
@ast
Potent and selective inhibitio ...... azinyloxoquinoline derivatives
@en
Potent and selective inhibitio ...... azinyloxoquinoline derivatives
@nl
prefLabel
Potent and selective inhibitio ...... azinyloxoquinoline derivatives
@ast
Potent and selective inhibitio ...... azinyloxoquinoline derivatives
@en
Potent and selective inhibitio ...... azinyloxoquinoline derivatives
@nl
P2093
P2860
P356
P1476
Potent and selective inhibitio ...... azinyloxoquinoline derivatives
@en
P2093
Sakaguchi T
P2860
P304
P356
10.1128/AAC.41.6.1250
P407
P577
1997-06-01T00:00:00Z